255 related articles for article (PubMed ID: 21150278)
1. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.
Garrido G; Tikhomirov IA; Rabasa A; Yang E; Gracia E; Iznaga N; Fernández LE; Crombet T; Kerbel RS; Pérez R
Cancer Biol Ther; 2011 Feb; 11(4):373-82. PubMed ID: 21150278
[TBL] [Abstract][Full Text] [Related]
2. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.
Zhou Y; Goenaga AL; Harms BD; Zou H; Lou J; Conrad F; Adams GP; Schoeberl B; Nielsen UB; Marks JD
Mol Cancer Ther; 2012 Jul; 11(7):1467-76. PubMed ID: 22564724
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.
Kearns JD; Bukhalid R; Sevecka M; Tan G; Gerami-Moayed N; Werner SL; Kohli N; Burenkova O; Sloss CM; King AM; Fitzgerald JB; Nielsen UB; Wolf BB
Mol Cancer Ther; 2015 Jul; 14(7):1625-36. PubMed ID: 25911688
[TBL] [Abstract][Full Text] [Related]
4. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.
Reilly EB; Phillips AC; Buchanan FG; Kingsbury G; Zhang Y; Meulbroek JA; Cole TB; DeVries PJ; Falls HD; Beam C; Gu J; Digiammarino EL; Palma JP; Donawho CK; Goodwin NC; Scott AM
Mol Cancer Ther; 2015 May; 14(5):1141-51. PubMed ID: 25731184
[TBL] [Abstract][Full Text] [Related]
5. Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrations.
Berger C; Krengel U; Stang E; Moreno E; Madshus IH
J Immunother; 2011 Sep; 34(7):550-5. PubMed ID: 21760527
[TBL] [Abstract][Full Text] [Related]
6. Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.
Bhuvaneswari R; Ng QF; Thong PS; Soo KC
Oncotarget; 2015 May; 6(15):13487-505. PubMed ID: 25918252
[TBL] [Abstract][Full Text] [Related]
7. EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo.
Zhou C; Zhu L; Ji J; Ding F; Wang C; Cai Q; Yu Y; Zhu Z; Zhang J
Curr Cancer Drug Targets; 2017; 17(1):89-97. PubMed ID: 27739365
[TBL] [Abstract][Full Text] [Related]
8. Radiosensitization induced by the anti-epidermal growth factor receptor monoclonal antibodies cetuximab and nimotuzumab in A431 cells.
González JE; Barquinero JF; Lee M; García O; Casaco A
Cancer Biol Ther; 2012 Jan; 13(2):71-6. PubMed ID: 22231391
[TBL] [Abstract][Full Text] [Related]
9. Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies.
Diaz Miqueli A; Rolff J; Lemm M; Fichtner I; Perez R; Montero E
Br J Cancer; 2009 Mar; 100(6):950-8. PubMed ID: 19293809
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
Perez-Torres M; Guix M; Gonzalez A; Arteaga CL
J Biol Chem; 2006 Dec; 281(52):40183-92. PubMed ID: 17082181
[TBL] [Abstract][Full Text] [Related]
11. The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin.
Zhao L; Li QQ; Zhang R; Xi M; Liao YJ; Qian D; He LR; Zeng YX; Xie D; Liu MZ
Tumour Biol; 2012 Aug; 33(4):1115-23. PubMed ID: 22389159
[TBL] [Abstract][Full Text] [Related]
12. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
[TBL] [Abstract][Full Text] [Related]
13. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma.
Kurai J; Chikumi H; Hashimoto K; Takata M; Sako T; Yamaguchi K; Kinoshita N; Watanabe M; Touge H; Makino H; Igishi T; Hamada H; Yano S; Shimizu E
Int J Oncol; 2012 Nov; 41(5):1610-8. PubMed ID: 22922885
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
16. EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs.
James R; Vishwakarma S; Chivukula IV; Basavaraj C; Melarkode R; Montero E; Nair P
Cancer Med; 2012 Oct; 1(2):114-27. PubMed ID: 23342262
[TBL] [Abstract][Full Text] [Related]
17. Roles of autophagy in cetuximab-mediated cancer therapy against EGFR.
Li X; Lu Y; Pan T; Fan Z
Autophagy; 2010 Nov; 6(8):1066-77. PubMed ID: 20864811
[TBL] [Abstract][Full Text] [Related]
18. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities.
Diaz Miqueli A; Blanco R; Garcia B; Badia T; Batista AE; Alonso R; Montero E
Hybridoma (Larchmt); 2007 Dec; 26(6):423-31. PubMed ID: 18158788
[TBL] [Abstract][Full Text] [Related]
19. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.
Brockhoff G; Heckel B; Schmidt-Bruecken E; Plander M; Hofstaedter F; Vollmann A; Diermeier S
Cell Prolif; 2007 Aug; 40(4):488-507. PubMed ID: 17635517
[TBL] [Abstract][Full Text] [Related]
20. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor.
Emanuel SL; Engle LJ; Chao G; Zhu RR; Cao C; Lin Z; Yamniuk AP; Hosbach J; Brown J; Fitzpatrick E; Gokemeijer J; Morin P; Morse BA; Carvajal IM; Fabrizio D; Wright MC; Das Gupta R; Gosselin M; Cataldo D; Ryseck RP; Doyle ML; Wong TW; Camphausen RT; Cload ST; Marsh HN; Gottardis MM; Furfine ES
MAbs; 2011; 3(1):38-48. PubMed ID: 21099371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
